Can-Fite Biopharma (CANF) vs NeuroSense Therapeutics (NRSN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
NeuroSense Therapeutics is the larger company by market cap ($6.8 million vs $6.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | CANF | NRSN |
|---|---|---|
| Share price | $2.00 | $3.58 |
| Market cap | $6.06M | $6.79M |
| 1-day change | -4.76% | -6.28% |
| YTD return | -50.00% | — |
| 1-year return | -83.05% | — |
| 5-year return | -99.35% | — |
| EPS (TTM) | $-13.23 | $-47.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.40 | $26.64 |
| 52-week low | $1.96 | $3.56 |
| Distance from 52-week high | -83.87% | -86.56% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +300.00% | +2618.72% |
| Average volume | 388.00K | 21.29K |
| Shares outstanding | 3.03M | 1.90M |
| Employees | 5 | 17 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Can-Fite Biopharma
CANF stock →Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis.
Healthcare · Biotechnology · 5 employees
About NeuroSense Therapeutics
NRSN stock →NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.
Healthcare · Biotechnology · 17 employees
CANF vs NRSN FAQ
Which is bigger, Can-Fite Biopharma or NeuroSense Therapeutics?
NeuroSense Therapeutics (NRSN) is larger, with a market capitalization of $6.79M compared with $6.06M for Can-Fite Biopharma (CANF).
Are Can-Fite Biopharma and NeuroSense Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.